Companies like Sana Biotechnology, Umoja Biopharma and Sonoma Biotherapeutics are heeding the call from the Tacoma mountains, making the BioForest region of Washington and Oregon a lucrative landing ground for biotech innovators. And if the rumors are to be believed, there could soon be a major player moving in.
Seattle, in particular, is a bastion for one of biopharmas hottest spaces cell and gene therapy.
You have a big focus on cell and gene therapies because you have the Hutch, which is really where the first cell therapy was developed, Andy Scharenberg, M.D., co-founder and CEO of Seattle-based Umoja told BioSpace. Scharenberg was referring to the storied Fred Hutchinson Cancer Research Center where bone marrow transplant pioneer Dr. E. Donnall Thomas discovered the potential for the human immune system to eliminate cancer.
Along with Umoja, Sana and Affini-T Therapeutics, both based in Seattle, are continuing this work. Umojas approach aims to re-engineer a patients immune system in vivo to attack and destroy both hematologic and solid organ-based tumors. Sana is a cell and gene therapy hybrid with a cloaking technology that works to overcome the immune barriers of allogeneic cells. Affini-T, launched by researchers at the Hutch, is pioneering engineered TCR T cell therapies with synthetic biology and gene editing enhancements to target oncogenic driver mutations.
Meanwhile, in December 2021, Seattle-based Tune Therapeutics announced its entrance into the sizzling epigenome editing space. This emerging field also consists of Omega Therapeutics and the brand new Epic Bio.
While Seattle gets the most attention, just to the south, Oregon is home to Sparrow Pharmaceuticals, NemaMetrix and Aronora, along with a host of scientific tools manufacturers including Araceli Biosciences and Grace Bio-Labs.
An Elite Talent Pool
BioForest-based companies are able to draw elite scientific talent from the Hutch as well as the University of Washington where Affini-T scientific co-founder Phil Greenberg maintains a teaching position. The Oregon State Universitys Center for Genome Research and Biocomputing offers another plentiful talent pool.
With established companies like Seagen in the region, there is also an ecosystem to provide management talent, Scharenberg said, noting that building a biotech requires good management.
Those factors, along with a relative affordability edge over the principle Biotech Bay and Genetown hubs have made Seattle a great place to build new biotechs, he said. You're seeing that with an increasing amount of startup activity, and also the continued capacity to grow those into at least the mid-cap range.
Seagen, Scharenberg said, is an example of a biotech that's completely homegrown - just an absolutely fantastic success - and has spawned a ton of expertise in how you grow and operate a pharmaceutical company at every stage. People have spun out of that to all over the Seattle area.
BioForest is also just that, a forest, and that appeals to the current generation of biotech talent, Scharenberg said.
There is an increasing interest in doing things in the outdoors and Seattle is amazing for that. There's probably nowhere else in the country where you can drive an hour or go backcountry skiing and feel like you're practically in the wilderness. He added that the COVID-19 pandemic has possibly added to this sentiment.
These factors clearly spoke to Sonoma. The cell therapy company, which is focused on curing autoimmune and inflammatory disease, recently announced plans to build an 83,000-square-foot operations facility in Seattle. The site will be primarily dedicated to the research, development and manufacturing of novel regulatory T cell (Treg) therapies. Sonomas first target is rheumatoid arthritis, for which it is conducting IND-enabling studies.
Heidi Hagen, chief technical officer at Sonoma, told BioSpace the company expects to hire for more than 100 positions across the Seattle area.
Seattle has an established legacy of delivering many firsts in the field of cell therapy for oncology, and Sonoma Bio is leveraging these insights to deliver the next wave of innovation Tregcell therapies for autoimmune and inflammatory diseases, she said. Hagen added that Sonoma considered proximity to transportation infrastructure, talent, technology and [its] current operations when exploring prime locations for the center.
Hagen noted that the first active cell immunotherapy, Dendreon Pharmaceuticals Provenge, for prostate cancer, was developed and approved in the Seattle area. This accomplishment led to Juno Therapeutics, which was formed by former Dendreon executives and then acquired by Celgene (now BMS) for $9 billion. Juno raised a $176 million Series A in 2014, one of the largest early-stage biotech financing rounds at the time.
The Intersection of High-Tech and Biotech
The high concentration of companies like Amazon and Microsoft in the region provides an opportunity for integration of digital technology and medical science, Hagen noted. It is at this intersection of high-tech and biotech that new genetic innovations and streamlined means of medical diagnoses and product manufacturing can be achieved.
Sana President and CEO Steve Harr, M.D. told BioSpace the critical mass of talent, large companies, emerging companies, infrastructure, capital and high-quality cities in the BioForest region are converging to make Seattle a leader in important emerging areas such as cell therapy, antibody-drug conjugates and complex manufacturing.
Harr honed in on complex manufacturing in cell therapy, which he said has emerged as a core strength and differentiator of the region that is both growing and looks sustainable.
This talent, combined with a mix of large and emerging companies, has given the area the critical mass to be a sustainable life sciences hub, Harr continued. Seattles strong foundation in cell and gene therapy and oncology is what drew Sana to the area, he said.
The Future
Historically, Seattles successful biotechs have been acquired at the small- or mid-cap range, Scharenberg noted, adding that he anticipates we're going to see more and more successful biotechs that turn into operating companies, a little bit like Seagen.
What well hopefully continue to do is see companies like [Seagen] start from scratch, grow into the small- to mid-cap stage, but also eventually be successful and hang around and grow into successful commercial biotechs that gradually move into the large biotech category, he said.
Ultimately, When you have an ecosystem that can be anchored by one or two companies that are bigger like that, and then a smattering in the middle and a really active startup situation, that for me is a really healthy ecosystem, Scharenberg concluded.
According to Harr, BioForest is right on the cusp.
I am optimistic that the Seattle area has reached a critical mass that provides the momentum for inevitable success, he shared. That said, winners attract and grow the talent base and will remain critical to the regions success.
Of course, with Mercks potential acquisition of Seagen on the horizon the deal has reportedly been stalled by a disagreement over price the regions star could rise even higher. Only time will tell.
Featured Jobs on BioSpace
More here:
BioForest is Breaking Out with Innovation, Talent and Investment - BioSpace
- About the Gene Therapy Review - November 8th, 2009 [November 8th, 2009]
- Contribute an Article - November 8th, 2009 [November 8th, 2009]
- EBSCO Publishing Deal - November 8th, 2009 [November 8th, 2009]
- Advertising Opportunities - November 8th, 2009 [November 8th, 2009]
- Instructions for Authors - November 8th, 2009 [November 8th, 2009]
- Isis Collaboration With Ortho-McNeil Inc for Metabolic Diseases - November 8th, 2009 [November 8th, 2009]
- Dystrophin Gene Transfer safe in Duchenne muscular dystrophy - November 8th, 2009 [November 8th, 2009]
- Researchers Identify Gene for Rare Form of Spinal Muscular Atrophy - November 8th, 2009 [November 8th, 2009]
- Fatal brain cancer tamed by New gene therapy - November 8th, 2009 [November 8th, 2009]
- Gene therapy effective in fighting obesity in mice - November 8th, 2009 [November 8th, 2009]
- Genzyme gene therapy for people with peripheral artery disease failed in a clinical trial to help them regain some mobility - November 8th, 2009 [November 8th, 2009]
- Gene Therapy May Stall Inherited Emphysema - December 31st, 2009 [December 31st, 2009]
- Gene Therapy and Stem Cells Save Limb - December 31st, 2009 [December 31st, 2009]
- TNVitamins.com – $10 Off Of $50 order - May 7th, 2011 [May 7th, 2011]
- 15% Off Any PetAlive Order - May 7th, 2011 [May 7th, 2011]
- At PetAlive – $10 off order of $50 or more - May 7th, 2011 [May 7th, 2011]
- Native Remedies coupon – 5% Off Any Order - May 7th, 2011 [May 7th, 2011]
- Native Remedies – Save $5 coupon - May 7th, 2011 [May 7th, 2011]
- Welcome to the Gene Therapy Review - May 15th, 2011 [May 15th, 2011]
- Editorial Board - May 15th, 2011 [May 15th, 2011]
- Gene Therapy Job Board - May 15th, 2011 [May 15th, 2011]
- Corporate Membership - May 22nd, 2011 [May 22nd, 2011]
- Native Remedies coupon – 25% Off Any Order - May 29th, 2011 [May 29th, 2011]
- What is Gene Therapy? - June 19th, 2011 [June 19th, 2011]
- Research and Markets: Recent Advances in Cancer Research and Therapy - Increased Research on one of the Major Causes ... - April 25th, 2012 [April 25th, 2012]
- Gene Therapy part 2 - Video - April 30th, 2012 [April 30th, 2012]
- Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- CBS This Morning - Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- Engineering adenoviruses for gene therapy - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy (The General Explains) - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy - Animation - Video - April 30th, 2012 [April 30th, 2012]
- Microbiology Gene Therapy - Video - April 30th, 2012 [April 30th, 2012]
- Gene Therapy in Detail - Video - April 30th, 2012 [April 30th, 2012]
- Breakthrough in Haemophilia treatment - Video - April 30th, 2012 [April 30th, 2012]
- Virology Seminar - Gene Therapy - April 30th, 2012 [April 30th, 2012]
- Gene Therapy Video - Video - April 30th, 2012 [April 30th, 2012]
- Study: Gene Therapy for HIV Safe, But Effectiveness Still Unclear - May 4th, 2012 [May 4th, 2012]
- Gene Therapy Safe in Decade-Long HIV Study That May Widen Use - May 4th, 2012 [May 4th, 2012]
- Gene therapy for HIV safe, but effectiveness still unclear - May 4th, 2012 [May 4th, 2012]
- A Step Forward For Gene Therapy To Treat HIV - May 4th, 2012 [May 4th, 2012]
- A Media Event on Clinical Developments in Gene and Cell Therapy - May 4th, 2012 [May 4th, 2012]
- Families of SMA Awards New Funding to Advance a CNS Delivered Gene Therapy for Spinal Muscular Atrophy - May 4th, 2012 [May 4th, 2012]
- AIDS gene therapy safe -- is it a "cure"? - May 4th, 2012 [May 4th, 2012]
- Generational Achievements in Gene and Cell Therapy Honored at ASGCT 15th Annual Meeting - May 5th, 2012 [May 5th, 2012]
- Lewis speaks on gene therapy at Lexington Community Education event - May 7th, 2012 [May 7th, 2012]
- Penn researchers report a gene-therapy success - May 10th, 2012 [May 10th, 2012]
- Gene therapy for hearing loss: Potential and limitations - May 13th, 2012 [May 13th, 2012]
- Gene therapy extends mouse lifespan by 24 pc - May 16th, 2012 [May 16th, 2012]
- Gene therapy dramatically extends mouse lifespan - May 16th, 2012 [May 16th, 2012]
- Gene therapy may extend life: Study - May 16th, 2012 [May 16th, 2012]
- First gene therapy successful against aging-associated decline: Mouse lifespan extended up to 24% with a single ... - May 16th, 2012 [May 16th, 2012]
- Gene Therapy Extends Mouse Lifespan - May 16th, 2012 [May 16th, 2012]
- Gene Therapy for Brain Disease - May 17th, 2012 [May 17th, 2012]
- Children with rare, incurable brain disease improve after gene therapy - May 17th, 2012 [May 17th, 2012]
- FIRST Anti-Aging Gene Therapy (Brainstorm Ep72) - Video - May 23rd, 2012 [May 23rd, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency - May 25th, 2012 [May 25th, 2012]
- RetroSense Therapeutics Completes pre-IND Meeting for RST-001 - May 25th, 2012 [May 25th, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency, study suggests - May 26th, 2012 [May 26th, 2012]
- Alliance for Cancer Gene Therapy celebrates 10 years - May 29th, 2012 [May 29th, 2012]
- Research on gene therapy by Prasad Eye - June 1st, 2012 [June 1st, 2012]
- Baxter Announces Collaboration with Chatham Therapeutics for Factor IX Hemophilia B Gene Therapy Treatment - June 5th, 2012 [June 5th, 2012]
- Transgenomic Launches Breakthrough Blood-Based Cancer Gene Testing Technology at 2012 ASCO Annual Meeting - June 5th, 2012 [June 5th, 2012]
- Baxter Inks Deal with Chatham - June 6th, 2012 [June 6th, 2012]
- PIK3CA Gene Patent for Predicting Response to Targeted Therapy Issued – Exclusively Licensed to Transgenomic - June 11th, 2012 [June 11th, 2012]
- SalutarisMD Announces Positive Case Report of a New Investigational Wet AMD Therapy at ARVO - June 15th, 2012 [June 15th, 2012]
- Research and Markets: Gene Therapy - Global Strategic Business Report - 2012 - June 15th, 2012 [June 15th, 2012]
- New York Law Firm’s MesotheliomaHelp.net Site Publishes Interview with Gene Therapy Author - June 17th, 2012 [June 17th, 2012]
- uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy - June 19th, 2012 [June 19th, 2012]
- Anti-cocaine vaccine described in Human Gene Therapy Journal - June 19th, 2012 [June 19th, 2012]
- bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy - June 19th, 2012 [June 19th, 2012]
- Close to a cure: Greater Hartford takes on rare Jewish genetic disease - June 19th, 2012 [June 19th, 2012]
- Gene Therapy Helps Treat Children with Rare Brain Disorder - June 20th, 2012 [June 20th, 2012]
- Gold nanoparticles capable of 'unzipping' DNA - June 21st, 2012 [June 21st, 2012]
- ‘Gene-silencing’ drug can halt and reverse deadly brain disorder - June 21st, 2012 [June 21st, 2012]
- uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson's Disease - June 22nd, 2012 [June 22nd, 2012]
- Gene-silencing method offers possible therapy for Huntington's disease - June 22nd, 2012 [June 22nd, 2012]
- Gene mutations cause massive brain asymmetry - June 24th, 2012 [June 24th, 2012]
- Research and Markets: Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features ... - June 25th, 2012 [June 25th, 2012]
- Stress Blocks Gene That Guards Brain Against Depression - June 26th, 2012 [June 26th, 2012]
- Targeted gene therapy enhances treatment for Pompe disease - June 26th, 2012 [June 26th, 2012]